



Andrew Wu [AWU01@BECKMAN.COM]; Dr. Kathrin Hauch [KOLSCHOK@BECKMAN.COM]



Introduction

The importance of consistent clone screening is invaluable for cell line development and allows top clones to be confidently selected. Manual selection processes such as delivering multiple feeds and additives to individual shaker flasks by pipetting, sampling, and delivering to standalone analytical devices, and compiling data from multiple devices are all prone to human error. In addition, manual techniques may vary from operator to operator, which may contribute to variability in results. The Cydem VT Automated Clone Screening System automates these processes and allows for precise and repeatable clone selection. As an evolution of the BioLector (Beckman Coulter Life Sciences) microbioreactor, the Cydem VT bioreactor module features fine-tuned delivery of O₂, CO₂ and N₂ gases via micro-channeled chips to individual wells, which creates a stable environment for mammalian cell growth and antibody production. This is done with proportional-integral-derivative (PID) controlled feedback looping using real-time pH and DO data from calibrated optical sensors attached to the bottom of the microbioreactors. The sensors are read with the integrated fluorescent LED detection system. The shaking and temperature-controlled incubation chamber with sliding cover and fans is another a feature that ensures uniform shaking conditions and heating distribution. Scheduled feeds, base additions, and analytical tests also contribute to repeatable results by ensuring consistent nutrient delivery and testing times.



Figure 1: Cydem VT Bioreactor module. The bioreactor module provides uniform shaking and temperature conditions. The optical detection system provides in-process monitoring of pH and dissolved oxygen (DO) which triggers $N_{2'}$, O_2 and CO_2 gases to be delivered to individual wells via feedback loops.

Cell Health Uniformity 7- to 8-day Fed Batch Experiments

To demonstrate uniformity over the 96 microbioreactor wells of the Cydem VT system, CHO-K1 cultures cultured in the Cydem VT bioreactor module were sampled on various days and analyzed on the Cydem VT cell health analysis module for three 7- to 8-day fed-batch culture experiments. 50 mL bioreactor culture tubes were run in a shaking Eppendorf incubator with similar conditions as controls for each experiment. Base additions were not performed for culture tubes. A single clone of the CHO-K1 cell line was used for all experiments.

Cydem VT System Culture Conditions

A user-defined, Cydem VT system protocol with conditions of a 50% DO set point, 36.5° C and 800 rpm shaking speed was created. CO₂ and/or N₂ was flushed into the wells to lower or raise pH to a gassing adjusted setpoint of pH 7.0. The base addition target point was at pH 7.1, and base addition trigger point at pH 6.8. pH was regulated by the PID controlled feedback loops.

CHO-K1 cells were cultured in ActiPro (Cytiva) liquid medium supplemented with 6 mM Glutamine and 375 μ g/mL geneticin. On day 0, the initial stock culture was grown to approximately 4.0 E+06 viable cells per mL and diluted in fresh media to a cell density of 0.5 E+06 viable cells per mL in a final working stock volume of 500 mL. The initial stock culture concentrations and viability were determined using a Vi-CELL BLU cell viability analyzer. Bioreactor plates were manually seeded by pipetting 5 mL of cell suspension into each well. The process was repeated until all 4 bioreactor plates were seeded. Media-specific pH and DO optode calibration values were used. As a control, 10 bioreactor tubes with 5 mL of 0.5 E+06 viable cells per mL were incubated in an Eppendorf incubator with 5% CO₂ and 36.5 °C temperature at 250 rpm.

Feed and Additives

The experiment was set up to have Feed A and Feed B scheduled to be added daily on days 3-7 at 3% and 0.3%, respectively. 32 μ L of 400 g/L glucose was added to each well on day 6 based on a previously determined feeding strategy of feeding to 5 g/L when values drop below 3.5 g/L. The media specific scale factor was set to 180* and represents the amount in μ L of 6% Na₂CO₃ to be added to increase 10 mL of culture media by 1 pH unit. Base was added 2 times per day on a per well basis when the pH reached a value below the 0.1 unit set point. Feeds and glucose were placed on deck prior to their first use. Na₂CO₃ was placed on deck at the beginning of the experiment. The 50 mL bioreactor control tube cultures were fed manually with a pipette.

*Note: Scaling factor values should be determined and verified for specific experimental conditions.

Cydem VT System Cell Health Analysis

The technology of the cell health module is based on the Vi-CELL BLU cell viability analyzer and delivers the same consistent results. For cell health analysis, the Cydem VT system samples 43 µL from each microbioreactor using stainless steel fixed tips and delivers the sample to the cell health module at the scheduled times. The default mammalian cell type settings were used for analysis.

Cell Health Results

Uniformity was evaluated by examining the coefficients of variation percentages (CV%) of viable cell density (VCD) measurements for the microbioreactor replicates across all days for each experiment **(Figure 2)**. A variability plot of individual data points for day 7 Cydem VT system cell health data was compared to day 7 bioreactor tube controls analyzed with the Vi-CELL BLU cell viability analyzer **(Figure 3 and Table 1)**. Mean CV% of viable cell density across all days was 5.47% (N=576), 4.33% (N=576), and 4.99% (N=672) for experiments 1, 2, and 3, respectively **(Figure 2)**. On any given day for all experiments, CV% did not exceed 7.5% (data not shown). Sampling days varied for each experiment with days 1,2,3,4,7,8; 1,2,4,5,6,7; and 1,2,3,4,5,6,7 for experiments 1, 2 and 3, respectively. 96 replicates were measured on the Cydem VT system and 10 replicates for the 50 mL bioreactor tube controls per day for each experiment. Data was analyzed using JMP version 16.1.0.



Mean CV% Across All Days by Experiment

Figure 2: Mean CV% of VCD was calculated by taking the average CV% across all days for each Cydem VT Automated Clone Screening System experiment. Error bars are ±1 standard deviation (SD) from the mean. CV% did not exceed 7.5% on any day for any experiment. Sampling days varied for each experiment with days 1, 2, 3, 4, 7, 8; 1, 2, 4, 5, 6, 7; and 1, 2, 3, 4, 5, 6, 7 for experiments 1, 2 and 3 respectively (N=576, 576, and 672 replicates for experiments 1, 2 and 3, respectively).

Cell Health Day 7 Variability



Figure 3: Day 7 variability chart for 3 experiments on the Cydem VT system and with 50 mL bioreactor tubes in a shaking Eppendorf incubator. 1, 2, and 3 refer to experiments 1, 2, and 3, respectively.

Test	VCD Mean [x10 ⁶ cells/mL]	Std Dev	CV%	VCD Range [x10 ⁶ cells/mL]	Replicates
Cydem 1	21.54	0.73	3.41	3.74	96
Cydem 2	22.60	0.66	2.93	3.30	96
Cydem 3	24.45	0.65	2.65	3.91	96
Tubes 1	21.20	1.19	5.63	4.00	10
Tubes 2	24.20	1.21	5.00	4.40	10
Tubes 3	26.48	1.33	5.03	4.80	10

Table 1: Day 7 VCD Mean, standard deviation, CV%, and VCD Range for 3 experiments run on the Cydem VT system and for 50 mL bioreactor tube controls.

Cell Health and Titer Uniformity for Single Clone, 96-Well, 12- to 14-Day Fed-batch Experiments

To characterize the performance of the system in 12- to 14-day fed-batch culture runs, two experiments (FB1 and FB2) were conducted, each with a different monoclonal antibody producing clone (1 and 7). Ninety-six replicates of each clone were seeded for each experiment. Cell heath and titer results were analyzed for uniformity.

Cydem VT System 12- to 14-Day Fed-Batch Culture Conditions

The CHO-K1 cells were cultured in ActiPro liquid medium supplemented with 6 mM glutamine. On day 0, the initial stock culture was diluted in fresh media to a cell density of 2.14 E+06 viable cells per mL in a final working stock volume of 1.5 mL per well in 4x24 deep well source plates. The initial stock culture concentrations and viability were determined using a Vi-CELL BLU cell viability analyzer. Bioreactor plates were seeded from the prepared 24-well known VCD initial source plates using the **Known VCD Normalization** workflow in the **Additional Workflows** menu. The final target volume for each microbioreactor was 5 mL with a 4 mL media prefill volume and target density of 0.3 E+06 cells/mL. A 10 and 20% seeding adjustment factor* was applied to FB2 and FB1 respectively to prevent over-seeding during the suspension transfer process. Media-specific pH and DO optode calibration values were used.

A Cydem VT system protocol with conditions of a 40% DO setpoint, 36.5° C and 800 rpm shaking speed was created. CO₂ and/or N₂ was automatically flushed into the wells to lower or raise pH to the gassing adjusted setpoint of pH 7.2. The base addition target point was set to pH 7.1, and base addition trigger point to pH 7.0. pH1 was regulated by the PID controlled feedback loops.

*Note: A 10% adjustment will assume cells will be overseeded by 10% and reduce the suspension volume added to the well. The factor should be determined and verified for specific experimental conditions.

Feed and Additives

The experiments were set up to have Feed A and Feed B scheduled to be added daily on days 3-11 at 3% and 0.3%, respectively. 11-50 μ L of 400 g/L glucose was added to each well starting on day 5 based on a previously determined feeding strategy of feeding to 4 g/L on day 5 and to 5 g/L on days 6 and after. The media specific pH scale factor was set to 180* and represents the amount in μ L of 0.5 M NaOH to be added to increase 10 mL of culture media by 1 pH unit. Base was added 2 times per day** on a per well basis when the pH reached a value below the 7.1 base addition set1point. Feeds and glucose were placed on deck prior to their first use. NaOH was placed on deck at the beginning of the experiment.

*Note: Scaling factor values should be determined and verified for specific experimental conditions.

**Two days of base additions were skipped for FB1 due to insufficient base volume.

Cydem VT System IgG Titer Analysis

The technology of the fluorescent polarization titer module is based on the Valita Titer IgG assay. For IgG titer analysis, the Cydem VT system samples 10 μ L from each microbioreactor using stainless steel fixed tips, delivers the sample to the titer plate preparation station and then transfers the prepared sample to the titer module at the scheduled times. For more information on the fluorescent polarization principle and assay please refer to the Cydem VT system Instructions for Use (IFU) manual.

Cell Health Results

Uniformity was evaluated by examining the coefficients of variation percentages (CV%) of viable cell density (VCD) measurements for the microbioreactor replicates across all days for each experiment **(Figure 4)**. Mean CV% values across all days did not exceed 10% for either experiment. Variability plots were generated for each day **(Figure 5)**. Results with warnings were treated as outliers and removed from the analysis, and days with mean viability values below 95% were not included in the CV% analysis. Data was analyzed using JMP version 16.1.0.

Cell Health Variability



Figure 4: Viable cell density per day. Cell death began around day 10 for fed-batch experiment 1 (FB1; Clone 1) and day 11 for fed-batch experiment 2 (FB2; Clone 7).



Cell Health CV%

Figure 5: Viable cell density CV% values per day by experiment. CV% values increased during the exponential growth phase and decrease as they plateau into the stationary growth phase. CV% values are elevated after the peak growth phase when cell death occurs sporadically across wells at different rates. Mean CV% values averaged across days were 8.34% and 4.90% for FB1 and FB2 respectively when viability is >95%. CV% values for mean viability <95% were removed from analyses. FB1 exhibits higher mean CV% values than FB2 due to the inclusion of day 10 results which includes some wells with declining VCD due to cell death (see Figure 4; FB1 Day 10).

Titer Results

Uniformity was evaluated by examining the coefficients of variation percentages (CV%) of IgG titer measurements for the microbioreactor replicates across all days for each experiment (Figure 6). Mean CV% values across all days did not exceed 10% for either experiment. Variability plots were generated for each day (Figure 7). Results with cell health and titer warnings were treated as outliers and removed from the analysis. Data was analyzed using JMP version 16.1.0.

Titer Variability



Figure 6: Cumulative IgG titer per day by experiment. Clones displayed similar variability profiles during each experiment.



Titer CV%

Figure 7: IgG titer CV% by experiment. CV% is lowest near peak titer production around days 10 and 11. Mean CV% values averaged across days were 7.77% and 7.91% for FB1 and FB2 respectively.

Conclusion

The Cydem VT Automated Clone Screening System consistently demonstrated a uniform growth pattern, with a mean coefficient of variation (CV%) of VCD below 5.5% across all days for all three 7- to 8-day fedbatch experiments. Moreover, the CV% of VCD on day 7 was lower in the Cydem VT system compared to the 50 mL bioreactor tube controls in all experiments. This can be attributed to the system's temperature uniformity, constant shaking speed, and feedback loop mediated gas regulation, which ensured consistent and repeatable growth conditions across multiple experiments. For the 12- to 14-day fed-batch experiments, mean cell health CV% values across days with mean viability >95% and titer CV% values across all days from both experiments remained <10%. Overall, the Cydem VT system consistently delivers reliable and predictable cell health and titer results for 1-2 weeklong mammalian cell culture experiments.

Product not for use in diagnostic or therapeutic procedures.

Some data represented herein has been collected on development systems.

This method is for demonstration only and is not validated by Beckman Coulter. Beckman Coulter makes no warranties express or implied with respect to this protocol, including warranties of fitness for a particular purpose or merchantability or that the protocol is non-infringing. Your use of the method is solely at your own risk, without recourse to Beckman Coulter.

© 2025 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States, and other countries. Valita, Valita Titer, and the ValitaCell logo are trademarks or registered trademarks of ValitaCell Ltd in the United States and other countries. ValitaCell is a Beckman Coulter Company. All other trademarks are the property of their respective owners.





For Beckman Coulter's worldwide office locations and phone numbers, please visit Contact Us at beckman.com 2024-GBL-EN-105883-V3